Orexo announces positive data for powder-based intranasal vaccine formulated with the AmorphOX technology

Orexo Sweden

The study was conducted in partnership with Abera Bioscience, a platform and vaccine developer with over 30 years of research in the medical, molecular and microbiological fields.Both formulations tested induced strong systemic antibody response in serum (IgG) as well as locally in the nose and lungs (IgA).The collaboration is in line with Orexo's strategy to broaden the use of its powder-based drug delivery technology, AmorphOX®.View original content:https://www.prnewswire.co.uk/news-releases/orexo-announces-positive-data-for-powder-based-intranasal-vaccine-formulated-with-the-amorphox-technology-302425436.html